YM merges with Cytopia in $Cdn12mm deal
YM Biosciences (therapeutics for cancer and pain) has agreed to merge with Australia's Cytopia (oncology focused, with other treatments for cardiovascular, autoimmune, and inflammatory conditions). YM will issue one of its common shares for every 11.737 Cytopia shares, or an aggregate of 7.2mm shares valued at $Cdn12mm ($11.1mm). The per share ratio of $Cdn0.17 represents a 55% premium.
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Stock
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.